- Home
- DENN vs ESPR Comparison
DENN vs ESPR Comparison
Compare DENN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DENN
- ESPR
- Stock Information
- Founded
- DENN 1953
- ESPR 2008
- Country
- DENN United States
- ESPR United States
- Employees
- DENN N/A
- ESPR N/A
- Industry
- DENN Restaurants
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- DENN Consumer Discretionary
- ESPR Health Care
- Exchange
- DENN Nasdaq
- ESPR Nasdaq
- Market Cap
- DENN 329.8M
- ESPR 319.2M
- IPO Year
- DENN 1989
- ESPR 2013
- Fundamental
- Price
- DENN $6.54
- ESPR $2.12
- Analyst Decision
- DENN Strong Buy
- ESPR Buy
- Analyst Count
- DENN 5
- ESPR 4
- Target Price
- DENN $7.70
- ESPR $8.17
- AVG Volume (30 Days)
- DENN 798.7K
- ESPR 4.8M
- Earning Date
- DENN 10-22-2024
- ESPR 11-07-2024
- Dividend Yield
- DENN N/A
- ESPR N/A
- EPS Growth
- DENN N/A
- ESPR N/A
- EPS
- DENN 0.33
- ESPR N/A
- Revenue
- DENN $453,013,000.00
- ESPR $295,451,000.00
- Revenue This Year
- DENN N/A
- ESPR $198.22
- Revenue Next Year
- DENN $4.07
- ESPR $25.83
- P/E Ratio
- DENN $19.99
- ESPR N/A
- Revenue Growth
- DENN N/A
- ESPR 187.12
- 52 Week Low
- DENN $5.37
- ESPR $1.08
- 52 Week High
- DENN $11.16
- ESPR $3.40
- Technical
- Relative Strength Index (RSI)
- DENN 48.49
- ESPR 50.12
- Support Level
- DENN $6.34
- ESPR $1.87
- Resistance Level
- DENN $7.73
- ESPR $2.60
- Average True Range (ATR)
- DENN 0.30
- ESPR 0.17
- MACD
- DENN -0.03
- ESPR -0.01
- Stochastic Oscillator
- DENN 14.39
- ESPR 34.25
About DENN Denny's Corporation
Denny's Corp is one of America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.